Vanda Pharmaceuticals, Inc. (VNDA)
5.20
-0.07
(-1.33%)
USD |
NASDAQ |
Dec 04, 16:00
5.55
+0.35
(+6.73%)
Pre-Market: 08:20
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 307.30M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 7.44% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.440 |
| Price to Book Value | 0.6594 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0234 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 89.26% |
Profile
| Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC. |
| URL | http://www.vandapharma.com |
| Investor Relations URL | https://www.vandapharma.com/investors |
| HQ State/Province | District of Columbia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 11, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC. |
| URL | http://www.vandapharma.com |
| Investor Relations URL | https://www.vandapharma.com/investors |
| HQ State/Province | District of Columbia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 11, 2026 (est.) |
| Last Earnings Release | Oct. 29, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |